The Septic Shock 3.0 definition and trials: A vasopressin and Septic Shock trial experience

Critical Care Medicine

Volumn 45, Issue 6, 2017, Pages 940-948

  Russell, James A ^a,b   Lee, Terry ^b   Singer, Joel ^b   Boyd, John H ^a,b   Walley, Keith R ^a,b   Gordon, A C ^aa   Cook, D J ^l,aa   Presneill, J J ^v,aa   Storms, M M ^aa   Boulton, C L Holmes ^aa   Jones, S ^aa   Bernard, G R ^aa   Slutsky, A S ^aa   Wells, G A ^aa   Gasparini, A ^aa   Savage, B ^aa   Ayers, D ^aa   Woods, R ^aa   Wu, K ^aa   Maralit, M ^aa   Howe, B ^aa   Higgins, A ^aa   LeBlanc, M E ^aa   Sutherland, A M ^aa   Sham, A ^aa   McLeod, A ^aa   Dorscheid, D R ^a   Hameed, M ^a   Lazosky, L ^a   Helderweirt, S ^a   Foley, K ^a   Honeyman, C ^a   Terins, T ^a   Chittock, D ^c   Ronco, J ^c   Smith, L ^c   Logie, S ^c   Wood, G ^d   Auld, F ^d   Boulton, C Holmes ^e   Stedham, V ^e   Mantle, M ^e   Fox, L ^e   McCauley, G D ^e   Rolf, J D ^e   Erbacher, C ^e   Martinka, G ^f   Goulding, S ^f   Silverwood, S ^f   Leung, L ^f   Keenan, S ^g   Murray, J ^g   Van Osch, M ^g   Light, B ^h   Dominique, M ^h   Gray, P ⁱ   Stimpson, R ⁱ   Rosser, S ⁱ   Bell, D ⁱ   Janz, W ⁱ   Hebert, P C ^j   McArdle, T ^j   Watpool, I ^j   Granton, J T ^k   Steinberg, M ^k   Matte Martyn, A ^k   McDonald, E ^l   Clarke, F ^l   Tkaczyk, A ^l   Zytaruk, N ^l   Mehta, S ^m   Stewart, T ^m   Suri, A ^m   Martinez Motta, C ^m   MacDonald, R ^m   Sivanantham, V ^m   Hodder, R ^j   Foxall, J ^j   Lewis, M ^j   Ward, M ⁿ   Dos Santos, C ⁿ   Friedrich, J ⁿ   Scales, D ⁿ   Smith, O ⁿ   DeCampos, I ⁿ   Richards, A ⁿ   Michalopoulos, H ⁿ   Bakshi, U ⁿ   Sibbald, W ^o   Smith, T ^o   Code, K ^o   Bojilov, B ^o   Dale, C ^o   Keogh, M ^o   Meade, M ^p   Hand, L ^p   Martin, C ^q   Kehoe, J ^q   Binns, V ^q   Mehta, M ^r   McGuire, M ^r   Poirier, G ^s   Provost, L ^s   Muscedere, J ^t   Diemer, C ^t   Cooper, D J ^u   Pellegrino, V ^u   Hilton, A ^u   Morrison, S ^u   Weatherburn, C ^u   Moulden, K ^u   Harry, C ^u   Robertson, M S ^v   Cade, J F ^v   Howe, B D ^v   Barge, D K ^v   Boyce, C A ^v   Healy, F ^v   Wright, C ^w   Weyandt, D ^w   Barrett, J ^w   Walker, C ^w   Galt, P ^w   Burton, S ^w   Dobb, G ^x   Perryman, S ^x   Chamberlain, J ^x   Thomas, L ^x   Bersten, A ^y   Daly, L ^y   Hunt, T ^y   Wood, D ^y   Patel, B ^z   Larson, J ^z   Rady, M ^z   LeBrun, G ^z   Boyd, E ^z   Rush, R ^z   more..

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d ROYAL JUBILEE HOSPITAL   (Canada)

^e KELOWNA GENERAL HOSPITAL   (Canada)

^f Division of Infectious Diseases   (Canada)

^g ROYAL COLUMBIAN HOSPITAL   (Canada)

^h ST BONIFACE GENERAL HOSPITAL   (Canada)

ⁱ HEALTH SCIENCES CENTRE   (Canada)

^j UNIVERSITY OF OTTAWA   (Canada)

^k TORONTO WESTERN HOSPITAL   (Canada)

^l ST JOSEPH S HOSPITAL   (Canada)

^m MOUNT SINAI HOSPITAL   (Canada)

ⁿ ST MICHAEL'S HOSPITAL   (Canada)

^o SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^p HAMILTON HEALTH SCIENCES   (Canada)

^q LONDON HEALTH SCIENCES CENTRE   (Canada)

^r SUDBURY REGIONAL HOSPITAL   (Canada)

^s HÔPITAL CHARLES LEMOYNE   (Canada)

^t Hotel Dieu Grace Hospital Windsor   (Canada)

^u ALFRED HOSPITAL   (Australia)

^v ROYAL MELBOURNE HOSPITAL   (Australia)

^w MONASH MEDICAL CENTRE   (Australia)

^x ROYAL PERTH HOSPITAL   (Australia)

^y FLINDERS MEDICAL CENTRE   (Australia)

^z Mayo Hospital   (United States)

^aa Mayo Hospital ^*

more..

Author keywords

Norepinephrine; Outcomes; Septic shock definition; Vasopressin

Indexed keywords

ALPHA2 INTERFERON; CXCL1 CHEMOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LACTIC ACID; NORADRENALIN; VASOPRESSIN; BIOLOGICAL MARKER; CYTOKINE; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ARTERIAL PRESSURE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; LACTATE BLOOD LEVEL; LEUKOCYTE COUNT; MORTALITY RATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK REDUCTION; SEPTIC SHOCK; BLOOD; CLINICAL TRIAL; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; METHODOLOGY; MORTALITY; MULTICENTER STUDY; SHOCK, SEPTIC;

BIOMARKERS; CYTOKINES; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; LACTIC ACID; NOREPINEPHRINE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 85015898501     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002323     Document Type: Article

References (18)

1. Singer M, Deutschman CS, Seymour CW, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801-810
2. Deutschman CS: Imprecise medicine: The limitations of sepsis-3. Crit Care Med 2016; 44:857-858
3. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887
4. Russell JA, Fjell C, Hsu JL, et al: Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 2013; 188:356-364
5. Ringnér M: What is principal component analysis? Nat Biotechnol 2008; 26:303-304
6. Helmy A, Antoniades CA, Guilfoyle MR, et al: Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS One 2012; 7:e39677
7. Glass DC, Gray CN: Estimating mean exposures from censored data: Exposure to benzene in the Australian petroleum industry. Ann Occup Hyg 2001; 45:275-282
8. Marshall JC: Sepsis-3: What is the meaning of a definition? Crit Care Med 2016; 44:1459-1460
9. Kempker JA, Martin GS: The changing epidemiology and definitions of sepsis. Clin Chest Med 2016; 37:165-179
10. Sprung CL, Reinhart K: Definitions for sepsis and septic shock. JAMA 2016; 316:456-457
11. Townsend SR, Rivers E, Tefera L: Definitions for sepsis and septic shock. JAMA 2016; 316:457-458
12. Schneider-Lindner V, Lindner HA, Thiel M: Definitions for sepsis and septic shock. JAMA 2016; 316:457
13. Shankar-Hari M, Singer M: Defining septic shock-reply. JAMA 2016; 316:456
14. Shankar-Hari M, Phillips GS, Levy ML, et al; Sepsis Definitions Task Force: Developing a new definition and assessing new clinical criteria for septic shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:775-787
15. Kaukonen KM, Bailey M, Suzuki S, et al: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311:1308-1316
16. Angus DC: Opening the debate on the new sepsis definition defining sepsis: A case of bounded rationality and fuzzy thinking? Am J Respir Crit Care Med 2016; 194:14-15
17. Russell JA, Walley KR: Vasopressin and its immune effects in septic shock. J Innate Immun 2010; 2:446-460
18. Bentzer P, Fjell C, Walley KR, et al: Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive Care Med 2016; 42:1970-1979